English News in Levels

Hope for the Deadliest Cancer: New Drug Daraxonrasib Targets the Gene Mutation Driving 90% of Pancreatic Tumors

A new cancer drug called daraxonrasib has shown remarkable results in Phase 3 clinical trials for pancreatic cancer, one of the most lethal forms of cancer with a five-year survival rate of only 12 percent. The drug directly targets the KRAS gene mutation found in approximately 90 percent of pancreatic cancers. Scientists are describing the results as the most significant advance in pancreatic cancer treatment in decades.